6:02 PM
 | 
Dec 13, 2012
 |  BC Extra  |  Clinical News

Rigel falls on Phase IIb data for RA compound

Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) fell $2.92 (35%) to $5.51 on Thursday after partner AstraZeneca plc (LSE:AZN; NYSE:AZN) said fostamatinib disodium monotherapy was inferior to active comparator Humira adalimumab in the Phase IIb OSKIRA-4 trial to treat rheumatoid arthritis. Specifically, all three dose regimens of oral fostamatinib missed the...

Read the full 239 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >